Potential for Weight-Loss Drugs Boosts Eli Lilly

Eli Lilly & Co.’s shares soared as its brighter outlook for 2024 raised the potential ceiling for new weight-loss drugs even further in the eyes of analysts and investors. Lilly says supply and pricing for Zepbound and the diabetes treatment Mounjaro will improve later this year. Bloomberg’s Madison Muller reports. (Source: Bloomberg)

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.